Cipla's Strategic Expansion Plans: US Market Entry from China and New Innovations

Cipla, a major pharmaceutical company, aims to begin supplying the US market from its China facility in the latter half of the fiscal year 2023-24 after receiving USFDA approval. The company is also addressing regulatory issues at various domestic plants and exploring new therapeutic areas and tech-based solutions.

Pharmaceutical giant Cipla plans to enter the US market from its China facility in the second half of the current fiscal year, following approval from the US Food and Drug Administration (USFDA), revealed managing director and global CEO Umang Vohra.

Addressing shareholders in Cipla's 2023-24 Annual Report, Vohra stated the company is collaborating closely with the USFDA to resolve compliance issues at its other plants. He highlighted that while the China facility has cleared its USFDA audit, the company's Patalganga and Kurkumbh plants in India have also received a voluntary action indicated status. Meanwhile, the Goa site received observations, and the Indore plant is undergoing remediation.

Vohra also disclosed Cipla's ambitious plans to delve into new therapeutic areas such as obesity-related diseases and liver conditions, while heavily investing in tech-based healthcare solutions. The Mumbai-based company is also focusing on combating antimicrobial resistance by developing a strong antimicrobial portfolio, including the introduction of the novel Plazomicin injection in India.

(With inputs from agencies.)